688278.SH
Xiamen Amoytop Biotech Co. Ltd.
SSE · Healthcare · Biotechnology · CN
CNY 59.47
−3.89%Price chart
Aug 20Aug 25Aug 28Sep 2Sep 7Sep 10Sep 15Sep 18
Key dataSep 18, 2026
OpenCNY 50.38
From 52W high−8.49%
Volume3.02M
Market capCNY 24.27B
P/E (TTM)23.5x
P/S (TTM)5.5x
Div yield1.20%
Key dataSep 18, 2026
Open
CNY 50.38
From 52W high
−8.49%
Volume
3.02M
Market cap
CNY 24.27B
ValuationView details →
P/E (Fwd)
30.5x
EV/EBITDA
14.6x
P/E (TTM)
23.5x
RSI (14)
37.0
MomentumView details →
1D Return
−3.89%
YTD Return
—
Similar companies
Latest newsMore news →
Four Shanghai-listed companies — Tebao Biology, Roborock, Espressif Systems and APT Medical — had repurchased 606 million, 318 million, 316 million and 300 million yuan of shares respectively as of September 11, 2026.7d agoSun Li, chairman of Xiamen Amoytop Biotech, disclosed that the company's 2025 revenue was 3.696 billion yuan and net profit attributable to shareholders was about 1.031 billion yuan, and said that in the first half of 2026 revenue grew more than 20% and net profit grew at a double-digit rate.9d agoAmoytop Biotech disclosed that as of August 31, 2026, its second buyback plan of 2026 had repurchased 7,381,464 shares, representing 1.81% of total share capital, for a cumulative amount of 407 million yuan, with the buyback price ranging from 52.62 to 57.20 yuan per share.19d ago